05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
Carolyn Cross |
156,314,029 |
£20,320,824 |
Nicolas Loebel |
3,538,991 |
£460,069 |
Junaid Bajwa |
1,193,697 |
£155,181 |
Jean Duvall |
1,163,529 |
£151,259 |
Jean Charest |
353,356 |
£45,936 |
Simon Sinclair |
256,327 |
£33,322 |
Carolyn Cross |
118,091,377 |
£15,351,879 |
M&G Plc |
40,588,235 |
£5,276,470 |
Robert Cross |
25,858,400 |
£3,361,592 |
Albemarle Life Sciences Fund |
15,105,882 |
£1,963,765 |
CRUX Asset Management |
9,298,090 |
£1,208,752 |
Chelverton Asset Management |
7,957,311 |
£1,034,450 |
16:21 |
50,000 @ 13.35p |
14:46 |
1,000 @ 12.59p |
12:57 |
1,150 @ 13.50p |
12:57 |
15,342 @ 13.08p |
10:38 |
18,000 @ 13.19p |
Chair |
Jean Charest |
CEO |
Carolyn Cross |
Top of Page
You are here:
research